SEC Form 3 · accession 0001104659-18-051573
Aridis Pharmaceuticals, Inc. · ARDS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Patzer
Director · 10% Owner
Period of report
Aug 13, 2018
Accepted (ET)
Aug 13, 2018 · 7:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001614067
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 709,606 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options | $13.16 | holding | — | — | — | Mar 1, 2017 | Oct 26, 2026 | Common Stock | 77,908 | — | D |
| Stock OptionsF1 | $9.63 | holding | — | — | — | — | Sep 22, 2027 | Common Stock | 38,954 | — | D |
Explanation of responses
- F1The Stock Options vest in equal installments over 48 months, beginning on September 22, 2017.